MannKind (MNKD) Financials: History & Chart

MannKind Corporation(MNKD)

Biotechnology · Danbury, CA

$3.73-0.09 (-2.38%)

Delayed quote: Oct 6, 2026, 3:40 PM EDT

About MannKind Corporation

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Danbury, CA

592 employees

www.mannkindcorp.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael E. Castagna

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	393.63M	109.37M	90.17M	111.95M	82.13M	76.53M	78.35M	76.78M	70.08M
Cost of Goods Sold	95.70M	29.54M	21.84M	24.12M	20.20M	20.57M	17.52M	19.60M	18.02M
Gross Profit	297.93M	79.83M	68.33M	87.83M	61.93M	55.96M	60.84M	57.17M	52.06M
Gross Profit Margin	75.7%	73.0%	75.8%	78.5%	75.4%	73.1%	77.6%	74.5%	74.3%
Total Operating Expenses	290.17M	80.18M	71.32M	95.52M	43.15M	50.66M	38.55M	30.68M	39.30M
Research & Development	76.88M	18.00M	17.23M	27.59M	14.06M	13.68M	11.02M	11.14M	12.93M
Selling, General & Administrative	199.89M	58.30M	54.09M	58.41M	29.09M	31.62M	25.01M	23.97M	23.92M
Operating Income (EBIT)	7.75M	-350K	-2.98M	-7.69M	18.78M	5.30M	22.29M	26.50M	12.76M
Operating Margin	2.0%	-0.3%	-3.3%	-6.9%	22.9%	6.9%	28.5%	34.5%	18.2%
Income Before Tax (EBT)	-48.65M	-19.14M	-16.37M	-20.93M	7.78M	940K	13.62M	8.45M	12.87M
Interest Income	7.84M	N/A	1.43M	3.79M	2.63M	1.83M	1.96M	2.83M	3.18M
Interest Expense	44.81M	11.89M	12.43M	13.15M	7.33M	6.19M	10.63M	7.48M	8.36M
Other Income/Expense	-56.41M	-18.79M	-13.38M	-13.24M	-10.99M	-4.36M	-8.68M	-18.05M	110K
Net Income	-43.61M	-19.03M	-16.62M	-15.95M	7.99M	668K	13.16M	7.42M	11.55M
Income Tax Expense	-5.04M	-106K	253K	-4.98M	-204K	272K	459K	1.02M	1.32M
Net Profit Margin	-11.1%	-17.4%	-18.4%	-14.2%	9.7%	0.9%	16.8%	9.7%	16.5%
EBITDA	28.55M	6.05M	3.40M	-2.42M	21.53M	7.92M	24.94M	29.18M	15.37M
EBITDA Margin	7.3%	5.5%	3.8%	-2.2%	26.2%	10.3%	31.8%	38.0%	21.9%
Depreciation & Amortization	20.80M	6.40M	6.38M	5.27M	2.75M	2.62M	2.65M	2.69M	2.61M
EPS Basic	-0.14	-0.06	-0.05	-0.05	0.03	0.00	0.04	0.03	0.04
EPS Diluted	-0.14	-0.06	-0.05	-0.05	0.03	0.00	0.04	0.03	0.04
Weighted Average Basic Shares	309.19M	309.19M	308.27M	305.64M	306.81M	304.95M	303.48M	279.19M	275.00M
Weighted Average Diluted Shares	309.19M	309.19M	308.27M	314.11M	311.64M	311.48M	320.90M	290.63M	284.69M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	348.97M	285.50M	198.96M	99.77M	75.44M	65.14M	63.04M	27.86M
Cost of Goods Sold	61.16M	76.60M	62.77M	57.50M	38.86M	24.64M	27.98M	20.48M
Gross Profit	287.81M	208.90M	136.19M	42.27M	36.59M	40.50M	35.06M	7.38M
Gross Profit Margin	82.5%	73.2%	68.5%	42.4%	48.5%	62.2%	55.6%	26.5%
Total Operating Expenses	249.00M	136.31M	127.51M	106.38M	83.61M	88.42M	79.66M	88.44M
Research & Development	66.35M	45.89M	31.28M	19.72M	12.31M	6.25M	6.90M	8.74M
Selling, General & Administrative	144.13M	94.33M	94.31M	91.47M	77.42M	59.04M	74.67M	79.72M
Operating Income (EBIT)	38.80M	72.59M	8.68M	-64.11M	-47.02M	-47.91M	-44.60M	-76.59M
Operating Margin	11.1%	25.4%	4.4%	-64.3%	-62.3%	-73.5%	-70.7%	-274.9%
Income Before Tax (EBT)	1.41M	30.52M	-10.38M	-87.40M	-80.93M	-57.46M	-51.90M	-86.73M
Interest Income	N/A	12.62M	6.15M	2.51M	112K	167K	997K	501K
Interest Expense	13.83M	37.98M	25.16M	24.77M	16.58M	9.47M	10.91M	9.44M
Other Income/Expense	-37.39M	-42.07M	-19.05M	-23.29M	-33.90M	-9.54M	-7.31M	-10.14M
Net Income	5.86M	27.59M	-11.94M	-87.40M	-80.93M	-57.24M	-51.90M	-86.97M
Income Tax Expense	-4.46M	2.93M	1.56M	0.00	0.00	-218K	0.00	240K
Net Profit Margin	1.7%	9.7%	-6.0%	-87.6%	-107.3%	-87.9%	-82.3%	-312.2%
EBITDA	51.09M	81.56M	13.21M	-57.80M	-43.78M	-44.59M	-42.44M	-74.89M
EBITDA Margin	14.6%	28.6%	6.6%	-57.9%	-58.0%	-68.4%	-67.3%	-268.8%
Depreciation & Amortization	12.28M	8.97M	4.54M	6.31M	3.24M	3.33M	2.15M	1.70M
EPS Basic	0.02	0.10	-0.04	-0.44	-0.37	-0.26	-0.31	-0.60
EPS Diluted	0.02	0.10	-0.04	-0.44	-0.37	-0.26	-0.31	-0.60
Weighted Average Basic Shares	305.64M	274.42M	267.01M	257.09M	249.24M	222.59M	195.58M	144.14M
Weighted Average Diluted Shares	314.11M	283.84M	267.01M	257.09M	249.24M	222.59M	195.58M	144.14M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.